Serum levels of placental protein 10 (PP10) were measured by radioimmunoassay in patients with trophoblastic (n=23) and non-trophoblastic (n=122) gynaecological tumours before, during and after treatment. Elevated levels (>2.0 μg/l) were found in 96% of patients with an untreated trophoblastic tumour, and in 22%, 20% and 12% of patients with endornetrial, cervical and ovarian carcinoma, respectively. After treatment the levels fell in patients with trophoblastic disease. Although PP10 may be tumour-associated in such cases, it is premature to assume any significance for PP10 as a tumour marker in clinical practice, because changes in serum hCG levels are much more informative.
- Nontrophoblastic gynaecological tumours
- Placental protein 10
- Trophoblastic tumours
ASJC Scopus subject areas
- Obstetrics and Gynaecology